Latest content

  • Top 8 biologics conferences of 2023 at a glance

    Top 8 biologics conferences of 2023 at a glance

    Use this downloadable list of 2023 biologics conferences to select which one to attend. Learn when and where they’ll happen, who’ll be there, and the main focus.

    Read
  • Four integrated technologies for Biologics developability assessment4:51

    Four integrated technologies for Biologics developability assessment

    The decisions you make about your biologics candidates early in the pipeline ultimately affect their success as therapeutics. Combine sizing and stability information to develop successful biologics

    Watch
  • How Coriolis Pharma screens a vast chemical library for stabilizing excipients1:39

    How Coriolis Pharma screens a vast chemical library for stabilizing excipients

    Discover how Coriolis Pharma found the best excipients to stabilize their monoclonal antibodies for long-term storage. You’ll learn about the importance of expanding the chemical space for excipients

    Watch
  • How Janssen optimizes the stability of a therapeutic mAb1:31

    How Janssen optimizes the stability of a therapeutic mAb

    Discover how Janssen improved the stability of a promising prostate cancer targeting mAb. You’ll learn why it is important to optimize stability measurements of a therapeutic mAb.

    Watch
  • How 2bind identifies the best buffer for a vaccine antigen target with Prometheus Panta2:34

    How 2bind identifies the best buffer for a vaccine antigen target with Prometheus Panta

    Discover how 2bind applied multi-parameter characterization from a single experiment to find the optimal buffer for a vaccine antigen target.

    Watch
  • 8 biologics conferences you won’t want to miss in 2023

    8 biologics conferences you won’t want to miss in 2023

    When you’re part of an industry that moves quickly, it’s important to keep up. You hear about biotherapeutics approvals, and big pharma news, but nothing matches the biologics conference experience.

    Read
  • ×

    Sign up to receive
    the latest NanoTemper news, product updates, event announcements and more

    First Name
    Last Name
    Company Name
    Country
    State
    Province
    State
    Region
    State
    Canton
    Agree to Subscribe & Privacy Policy*
    *I have fully read, understood and agree to the Privacy Policy. I accept the storing and processing of my personal data by NanoTemper as described in the Privacy Policy.

    By completing this form, you provide us consent to contact you with educational content, news and information about our products, services and events. You may unsubscribe at any time.
    Thank you!
    Error - something went wrong!
  • Learn the pros and cons of these 3 methods to serotype your AAV gene therapy vectors

    Learn the pros and cons of these 3 methods to serotype your AAV gene therapy vectors

    Read
  • Put your challenging affinity screening campaigns back on track — after you’ve tried everything else37:25

    Put your challenging affinity screening campaigns back on track — after you’ve tried everything else

    When you’re entrusted with developing therapeutics for challenging or undruggable targets, it’s a struggle to characterize molecular interactions. And it’s not for lack of effort or expertise — SPR an

    Watch
  • NanoTemper announces Monolith X with breakthrough Spectral Shift technology, enabling affinity measurements where other methods fail

    NanoTemper announces Monolith X with breakthrough Spectral Shift technology, enabling affinity measurements where other methods fail

    NanoTemper Technologies introduced Monolith X, adding breakthrough Spectral Shift technology to their top-selling Monolith product line.

    Read
  • Contact Specialist
  • Introducing Monolith X - the only way to get binding affinities in solution using very minimal sample2:20

    Introducing Monolith X - the only way to get binding affinities in solution using very minimal sample

    Watch
  • The only way to get binding affinities in solution using very minimal sample

    The only way to get binding affinities in solution using very minimal sample

    Read
  • Select the best biologics candidates with high-quality, multi-parameter stability characterization

    Select the best biologics candidates with high-quality, multi-parameter stability characterization

    Read
  • 5 benefits of optimizing your formulation buffer to get your AAV therapeutic approved

    5 benefits of optimizing your formulation buffer to get your AAV therapeutic approved

    As a gene therapy scientist, you face an abundance of challenges when working to build an effective AAV therapeutic. Many steps of the development workflow have yet to be standardized and the...

    Read
  • Characterize your PROTAC hook effect with flexible and in-solution affinity measurements for results you can trust

    Characterize your PROTAC hook effect with flexible and in-solution affinity measurements for results you can trust

    Read
  • Serotyping: why, when, and how to assess your AAV therapeutic to get it approved14:07

    Serotyping: why, when, and how to assess your AAV therapeutic to get it approved

    When you develop an AAV therapeutic, you need to assess many key parameters, or Critical Quality Attributes (CQAs), in order to track progress and, ultimately, get your therapeutic approved. As part

    Watch
  • Rely on Dianthus to overcome roadblocks in your PROTAC characterizations

    Rely on Dianthus to overcome roadblocks in your PROTAC characterizations

    Read
  • NanoTemper Technologies welcomes Andreas Schmitz as its first Chief Human Resources Officer

    NanoTemper Technologies welcomes Andreas Schmitz as its first Chief Human Resources Officer

    MUNICH, Germany, 18 May 2022 — NanoTemper Technologies, well-known for creating biophysical tools that tackle challenging characterizations, welcomes Andreas Schmitz as the first Chief Human...

    Read
  • 8 Gene Therapy conferences you should attend in 2022

    8 Gene Therapy conferences you should attend in 2022

    With the first AAV-based gene therapies approved, and new gene editing strategies emerging, it’s important to stay on top of the latest topics in this therapeutic area. Here are 8 gene therapy...

    Read
  • 9 Targeted Protein Degradation conferences you don’t want to miss in 2022

    9 Targeted Protein Degradation conferences you don’t want to miss in 2022

    With so much interest and investment in target protein degradation, a lot can happen in a year. Here are 9 conferences to get up-to-date on recent progress and the latest approaches. You’ll not...

    Read
  • Get more information about your protein expression conditions in less time with Andromeda

    Get more information about your protein expression conditions in less time with Andromeda

    Get more information about your protein expression conditions in less time with Andromeda

    Read
  • loading
    Loading more...